Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications

Recludix Pharma, Inc., a leading company in the discovery of inhibitors for challenging targets in inflammatory disease and cancer, has announced a strategic collaboration with Sanofi US (NASDAQ: SNY) to develop and market innovative oral small molecule STAT6 inhibitors. The goal of this collaboration is to advance the development of a preclinical oral STAT6 inhibitor for patients suffering from..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 21.
  • textsms

SK Bioscience and Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate

SK bioscience and Sanofi have announced positive results from the Phase II study of their 21-valent pneumococcal conjugate vaccine candidate, GBP410 (also known as SP0202). The vaccine demonstrated positive safety and immunogenicity data in infants. The companies plan to start Phase III trials in the first half of 2024. The Phase II clinical trial evaluated the safety and immunogenicity of GBP41..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 2.
  • textsms

AstraZeneca and Sanofi's Pediatric RSV Antibody Receives Unanimous Backing from FDA Panel

AstraZeneca and Sanofi have received unanimous backing from the FDA’s Antimicrobial Drugs Advisory Committee for their respiratory syncytial virus (RSV) antibody, nirsevimab, for use in the pediatric setting. Nirsevimab is an investigational long-acting antibody that targets and binds to the part of the RSV virus that attaches to the host’s cells. If approved, nirsevimab would become the first i..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 11.
  • textsms

AstraZeneca and Sanofi's Pediatric RSV Antibody Receives Unanimous Backing from FDA Panel

Pharmaceutical companies AstraZeneca and Sanofi have received unanimous approval from the FDA's Antimicrobial Drugs Advisory Committee for their respiratory syncytial virus (RSV) antibody, nirsevimab, to be used in pediatric settings. The committee voted 21-0 in favor of approving the immunizing antibody for use in infants during their first RSV season, while also recommending its approval for h..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 10.
  • textsms